Interleukin-6 polymorphism is associated with more aggressive prostate cancer

Journal of Urology

Volumn 174, Issue 2, 2005, Pages 753-756

  Tan, Dongfeng ^a   Wu, Xiuxian ^a   Hou, Min ^a   Lee, Soo Ok ^a   Lou, Wei ^a   Wang, Jianmin ^a   Janarthan, Bagirathan ^a   Nallapareddy, Sujatha ^a   Trump, Donald L ^a   Gao, Allen G ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Interleukin 6; Neoplasm recurrence; Polymorphism, genetic; Prostate; Prostatic neoplasms

Indexed keywords

CYTOSINE; GUANINE; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER STAGING; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENOTYPE; HOMOZYGOTE; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE TUMOR; RECURRENT CANCER;

EID: 22144440465     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000168723.42824.40     Document Type: Article

References (20)

1. Akira, S., Taga, T. and Kishimoto, T.: Interleukin-6 in biology and medicine. Adv Immunol, 54: 1, 1993
2. Hobisch, A., Rogatsch, H., Hittmair, A., Fuchs, D., Bartsch, G., Jr., Klocker, H. et al: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol, 191: 239, 2000
3. Giri, D., Ozen, M. and Ittmann, M.: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol, 159: 2159, 2001
4. Drachenberg, D. E., Elgamal, A. A., Rowbotham, R., Peterson, M. and Murphy, G. P.: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41: 127, 1999
5. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T. and Thompson, T. C.: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol, 161: 182, 1999
6. Zerbini, L. F., Wang, Y., Cho, J. Y. and Libermann, T. A.: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res, 63: 2206, 2003
7. Park, J. I., Lee, M. G., Cho, K., Park, B. J., Chae, K. S., Byun, D. S. et al: Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene, 22: 4314, 2003
8. Okamoto, M., Lee, C. and Oyasu, R.: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res, 57: 141, 1997
9. Deeble, P. D., Murphy, D. J., Parsons, S. J. and Cox, M. E.: Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol, 21: 8471, 2001
10. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H. et al: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res, 58: 4640, 1998
11. Lou, W., Ni, Z., Dyer, K., Tweardy, D. J. and Gao, A. C.: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 42: 239, 2000
12. Lee, S. O., Lou, W., Hou, M., de Miguel, F., Gerber, L. and Gao, A. C.: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res, 9: 370, 2003
13. Terry, C. F., Loukaci, V. and Green, F. R.: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275: 18138, 2000
14. Jones, K. G., Brull, D. J., Brown, L. C., Sian, M., Greenhalgh, R. M., Humphries, S. E. et al: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation, 103: 2260, 2001
15. Murray, R. E., McGuigan, F., Grant, S. F., Reid, D. M. and Ralston, S. H.: Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone, 21: 89, 1997
16. Linker-Israeli, M., Wallace, D. J., Prehn, J., Michael, D., Honda, M., Taylor, K. D. et al: Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun, 1: 45, 1999
17. Hefler, L. A., Grimm, C., Ackermann, S., Malur, S., Radjabi-Rahat, A. R., Leodolter, S. et al: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res, 63: 3066, 2003
18. Ye, S., Dhillon, S., Ke, X., Collins, A. R. and Day, I. N.: An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res, 29: E88, 2001
19. DeMichele, A., Martin, A. M., Mick, R., Gor, P., Wray, L., Klein-Cabral, M. et al: Interleukin-6-174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res, 63: 8051, 2003
20. McCarron, S. L., Edwards, S., Evans, P. R., Gibbs, R., Dearnaley, D. P., Dowe, A. et al: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res, 62: 3369, 2002